Evidence map›Paper›PMID 31267026›Full record

ArticleScientific reports2019

Oral Administration of Caffeine Exacerbates Cisplatin-Induced Hearing Loss.

Sandeep Sheth, Kelly Sheehan, Asmita Dhukhwa, Raheem F H Al Aameri, Chaitanya Mamillapalli, Debashree Mukherjea, Leonard P Rybak, Vickram Ramkumar

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.5field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Network-Based Identification ofCurrent pharmaceutical design · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Purinergic Signalling in the Cochlea.International journal of molecular sciences · 2022
    Review
  9. Long-term auditory follow-up in the management of pediatric platinum-induced ototoxicity.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2022
    Observational
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Sandeep ShethDepartment of Pharmacology, Southern Illinois University School of Medicine, Springfield, IL, United States.ORCID http://orcid.org/0000-0001-6570-8120
Kelly SheehanDepartment of Otolaryngology, Southern Illinois University School of Medicine, Springfield, IL, United States.
Asmita DhukhwaDepartment of Pharmacology, Southern Illinois University School of Medicine, Springfield, IL, United States.
Raheem F H Al AameriDepartment of Pharmacology, Southern Illinois University School of Medicine, Springfield, IL, United States.
Chaitanya MamillapalliDepartment of Internal Medicine (Division of Endocrinology), Southern Illinois University School of Medicine, Springfield, IL, United States.
Debashree MukherjeaDepartment of Otolaryngology, Southern Illinois University School of Medicine, Springfield, IL, United States.
Leonard P RybakDepartment of Otolaryngology, Southern Illinois University School of Medicine, Springfield, IL, United States.
Vickram RamkumarDepartment of Pharmacology, Southern Illinois University School of Medicine, Springfield, IL, United States. vramkumar@siumed.edu.
Southern Illinois University School of Medicine · US

Funding

ENDOGENOUS MODULATION OF OTOTOXICITY OF CISPLATINR01DC002396 · NIDCD · SOUTHERN ILLINOIS UNIVERSITY SCH OF MED · PI RYBAK, LEONARD P · 1994 to 2018
$4.7M
Oral Epigallocatechin Gallate (EGCG) for Treatment of Cisplatin OtotoxicityR01DC016835 · NIDCD · SOUTHERN ILLINOIS UNIVERSITY SCH OF MED · PI RYBAK, LEONARD P · 2018 to 2022
$2.2M
Transplatin: A Novel Agent to Mitigate Cisplatin ToxicityR01CA166907 · NCI · SOUTHERN ILLINOIS UNIVERSITY SCH OF MED · PI RAMKUMAR, VICKRAM · 2013 to 2017
$1.5M
NCI NIH HHS R01 CA166907NIDCD NIH HHS R01 DC002396NIDCD NIH HHS R01 DC016835U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA166907U.S. Department of Health & Human Services | NIH | National Institute on Deafness and Other Communication Disorders (NIDCD) R01DC002396U.S. Department of Health & Human Services | NIH | National Institute on Deafness and Other Communication Disorders (NIDCD) R01DC016835
6 · The paper itself

Abstract

Adenosine A

Indexed as

Administration, OralAnimalsAntineoplastic AgentsApoptosisBiomarkersCaffeineCentral Nervous System StimulantsCisplatinCochleaDrug SynergismFluorescent Antibody TechniqueHearing LossInflammationRatsSynaptic PotentialsAntineoplastic AgentsBiomarkersCaffeineCentral Nervous System StimulantsCisplatin

Identifiers

PMID31267026
PMCPMC6606569
OpenAlexW2954842655

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.